Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. The event can be accessed via a live webcast. Verrica specializes in dermatology therapeutics, with a focus on late-stage product candidates like VP-102 for treating molluscum, common warts, and external genital warts. Additionally, they are developing VP-103 for plantar warts and have a global licensing agreement with Lytix Biopharma to develop LTX-315 for dermatologic oncology conditions.

Positive

• CEO Ted White's presentation could enhance investor interest and confidence.
• VP-102 addresses major unmet medical needs in dermatology, potentially driving future revenue.
• Global license agreement with Lytix Biopharma could expand Verrica's market reach in dermatologic oncology.

Negative

• None.

WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. ET.

Participants may access a live webcast of the event through the following link:
https://wsw.com/webcast/jeff174/vrca/1848852

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com

FAQ

When will Verrica Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?

Verrica Pharmaceuticals will present on June 2, 2021, at 2:00 p.m. ET.

What is the focus of Verrica Pharmaceuticals?

Verrica Pharmaceuticals focuses on developing medications for skin diseases requiring medical interventions.

What product candidates is Verrica Pharmaceuticals developing?

Verrica is developing VP-102 for molluscum and warts, and VP-103 for plantar warts.

What is the significance of the licensing agreement with Lytix Biopharma?

The agreement allows Verrica to develop and commercialize LTX-315 for dermatologic oncology conditions.

Where can I access the live webcast of Verrica's presentation?

The live webcast can be accessed through Verrica's website or directly from the provided link in the press release.